Recently Featured

Supreme Court declines to hear IRA challenges from Novo, AZ and more

June 12, 2026
In a significant setback for the pharmaceutical industry, the United States Supreme Court has opted not to hear challenges to the Inflation Reduction Act (IRA) from major players including Novo Nordisk and AstraZeneca. This decision follows a series of legal defeats for the industry, which has sought to contest the provisions of the IRA that…

Supreme Court Rejects Legal Challenge to Medicare Drug Price Negotiation Program

June 12, 2026
WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program. The court declined to take up lawsuits against the program by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The justices did not provide a reason for…

U.S. Biotech Faces Dilemma Over Chinese Drug Partnerships Amid Record Investments

June 12, 2026
U.S. biotech firms are grappling with a significant dilemma regarding their relationships with Chinese drug manufacturers, as reported by STAT. In the first quarter of 2026 alone, American companies invested approximately $60 billion in Chinese-developed drugs, a figure projected to double last year’s total. This surge in investment highlights the growing reliance on Chinese innovations,…

Regeneron immunotherapy combo comes up short in melanoma trial

June 12, 2026
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value. The trial results raise questions about the competitive positioning of Regeneron’s immunotherapy portfolio, particularly in a market where efficacy and safety profiles are paramount for…

Ongoing Cases